A Phase 1 Trial to Evaluate the Safety of IL13Rα2-Targeting Chimeric Antigen Receptor (CAR) T Cells With CRISPR Knockout of TGFβR2 in Patients With Recurrent or Progressive High-Grade Glioma (HGG)
NCT06815029 · RECRUITING · Phase 1
ReadTheTrial indexes 1 studies for Recurrent Astrocytoma Idh Mutant Grade 3. The most common development stage is Phase 1 (1 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.
1 clinical trials found for Recurrent Astrocytoma Idh Mutant Grade 3.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
There are 1 clinical trials listed for Recurrent Astrocytoma Idh Mutant Grade 3. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.
Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.
Current Recurrent Astrocytoma Idh Mutant Grade 3 trials are distributed across: Phase 1 (1).